TY - JOUR
T1 - Cancer chemotherapy and beyond
T2 - Current status, drug candidates, associated risks and progress in targeted therapeutics
AU - Anand, Uttpal
AU - Dey, Abhijit
AU - Chandel, Arvind K.Singh
AU - Sanyal, Rupa
AU - Mishra, Amarnath
AU - Pandey, Devendra Kumar
AU - De Falco, Valentina
AU - Upadhyay, Arun
AU - Kandimalla, Ramesh
AU - Chaudhary, Anupama
AU - Dhanjal, Jaspreet Kaur
AU - Dewanjee, Saikat
AU - Vallamkondu, Jayalakshmi
AU - Pérez de la Lastra, José M.
N1 - Publisher Copyright:
© 2022 Chongqing Medical University
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.
AB - Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.
KW - Antimicrobial peptides
KW - Cancer therapies
KW - Clinical trials
KW - Combination therapy
KW - Immunotherapy
KW - Patient survival
KW - Personalized medicine
KW - Targeted drug delivery
UR - http://www.scopus.com/inward/record.url?scp=85128216238&partnerID=8YFLogxK
U2 - 10.1016/j.gendis.2022.02.007
DO - 10.1016/j.gendis.2022.02.007
M3 - Review article
C2 - 37397557
AN - SCOPUS:85128216238
SN - 2352-4820
VL - 10
SP - 1367
EP - 1401
JO - Genes and Diseases
JF - Genes and Diseases
IS - 4
ER -